Reshma Kuvelkar

Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation.

William Greenlee, Lynn Hyde, Xia Chen, 2012, Journal of medicinal chemistry.

Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation.

Lingyan Wang, Andrew Stamford, Michael Czarniecki, 2010, Journal of medicinal chemistry.

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.

Qin Jiang, William J Greenlee, Xia Chen, 2016, Journal of medicinal chemistry.

Discovery of potent iminoheterocycle BACE1 inhibitors.

Brian McKittrick, Andrew Stamford, Xia Chen, 2014, Bioorganic & medicinal chemistry letters.

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Michael Tanen, Matthew E. Kennedy, Wei Li, 2016, Science Translational Medicine.

Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization.

Andrew Stamford, William Greenlee, Guoqing Li, 2010, Bioorganic & medicinal chemistry letters.

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.

Marc Poirier, Michael W. Miller, Christian Mirescu, 2017, Journal of medicinal chemistry.

Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction.

Suresh Babu, William J Greenlee, Xia Chen, 2012, ACS medicinal chemistry letters.